The stage of amyloidosis is an important predictor of outcome. According to the revised Mayo Clinic staging system, patients were assigned a score of 1 for each of dFLC ≥18 mg/dL, cTnT ≥0.025 ng/mL, and NT-proBNP ≥1,800 pg/mL, creating stages I–IV with scores of 0–3 points.